Active substance
Salicylic acid
- SFDA 3
- US price lines 1
- NHS prices 4
- WHO EML 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| KERASAL 10 % OINTMENT | 10 % | Ointment · Topical | 1 Tube | SAR 14.80 | NCE · OTC | Dallah Pharma Factory | Valid |
| Kerasal | 5 % | Ointment · Topical | 1 Tube | SAR 14.80 | Generic · OTC | Dallah Pharma Factory | Valid |
| NOCAL 10% TOPICAL SOLN. | 10 % | Cutaneous solution · Topical | 1 Bottle | SAR 4.70 | NCE · OTC | ARAB CENTER FOR PHARMACEUTICALS & CHEMICAL IND. CO. | Withdrawn by regulatory authority · Not Marketed |
Indications — CHI Daman Drug Formulary
ONYCHOMYCOSIS ,TINEA UNGUIUM
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | SALICYLIC ACID 27.5% LIQUID | $5.60834 | per ML | 23 Sep 2026 |
| NHS Drug Tariff | Salicylic acid 26% gel | £4.71 | 5 gram | 1 Oct 2026 |
| NHS Drug Tariff | Salicylic acid 26% solution | £3.56 | 10 ml | 1 Oct 2026 |
| NHS Drug Tariff | Salicylic acid 40% medicated plasters | £2.58 | 8 plaster | 1 Oct 2026 |
| NHS Drug Tariff | Salicylic acid 40% medicated plasters | £3.23 | 30 plaster | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 13.4. Dermatological medicines > Medicines affecting skin differentiation and proliferation · core
Seborrhoeic dermatitis; Psoriasis of unspecified type; Ichthyoses
Local > Topical > Solution: 5%
Combinations containing Salicylic acid
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.